<table>
<thead>
<tr>
<th>Título artículo / Título article:</th>
<th>Centrally formed acetaldehyde mediates ethanol-induced brain PKA activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autores / Autors:</td>
<td>Tarragón Cros, Ernesto ; Baliño Remiro, Pablo ; González Aragón, Carlos Manuel</td>
</tr>
<tr>
<td>Revista:</td>
<td>Neuroscience letters</td>
</tr>
<tr>
<td>Versión / Versió:</td>
<td>Pre-print</td>
</tr>
<tr>
<td>url Repositori UJI:</td>
<td><a href="http://hdl.handle.net/10234/127657">http://hdl.handle.net/10234/127657</a></td>
</tr>
</tbody>
</table>
Highlights

- EtOH administration in vivo enhances PKA activity in the brain
- cAMP-PKA pathway is involved in the behavioral response to EtOH
- Centrally formed acetaldehyde is responsible for several effects induced by EtOH
- EtOH-induced PKA activation is reduced when central acetaldehyde activity decreases
- cAMP-PKA signaling cascade promoted by EtOH in vivo is dependent on acetaldehyde
CENTRALLY FORMED ACETALDEHYDE MEDIATES ETHANOL-INDUCED BRAIN PKA ACTIVATION

Tarragon E 1,2, Baliño P 1,2, Aragon CMG 1*

1 Área de Psicobiología, Universitat Jaume I, Castellon de la Plana (SPAIN); 2 Authors contributed equally to this work

* Corresponding author:
Prof. Carlos M. G. Aragón, PhD
Dept. Psychobiology
Universitat Jaume I
Avinguda Vicent Sos Baynat, s/n
E-12071 Castelló de la Plana (Spain)
Tel.: +34 964729835
aragon@psb.uji.es

Abstract
Centrally formed acetaldehyde has proven to be responsible for several psychopharmacological effects induced by ethanol. In addition, it has been suggested that the cAMP-PKA signaling transduction pathway plays an important role in the modulation of several ethanol-induced behaviors. Therefore, we hypothesized that acetaldehyde might be ultimately responsible for the activation of this intracellular pathway. We used three pharmacological agents that modify acetaldehyde activity (α-Lipoic acid, aminotriazole, and D-penicillamine) to study the role of this metabolite on EtOH-induced PKA activation in mice. Our results show that the injection of α-Lipoic acid, aminotriazole and D-penicillamine prior to acute EtOH administration effectively blocks the PKA-enhanced response to EtOH in the brain. These results strongly support the hypothesis of a selective release of acetaldehyde-dependent Ca2+ as the mechanism involved in the neurobehavioral effects elicited by EtOH.

Keywords: acetaldehyde, PKA, ethanol
Introduction

Ethanol (EtOH) is one of the most widely consumed substances of abuse, and yet the molecular mechanism by which it exerts its effects on behavior is still not understood [1]. It is known that EtOH is centrally metabolized into acetaldehyde by a combination of the enzyme catalase and hydrogen peroxide (H2O2) [2-4]. This central metabolite has been shown to be responsible for some of the behavioral and neurophysiological effects elicited by EtOH [5,6]. In this sense, there is evidence showing that the manipulation of central acetaldehyde through the α-Lipoic acid (LA) scavenging of H2O2 [7-10], the catalase inhibition by 3-amino-1,2,4-triazole (aminotriazole, AT) [3,11-13], and acetaldehyde inactivation by D-penicillamine (D-Pen) [14-18] are capable of preventing different behavioral outcomes resulting from acute EtOH exposure.

The cAMP-PKA cellular signaling pathway has been described as an important mechanism involved in the neurobiological response to EtOH [19,20]. There is evidence in vitro and in vivo showing an activation of the cAMP signaling cascade following EtOH exposure [21-24]. In addition, it has been demonstrated that manipulations of the cAMP-PKA pathway modulate some of the EtOH-induced responses at the behavioral level [25,26]. Therefore, the PKA activity elicited by EtOH has been suggested as critical in some behavioral effects induced by this alcohol. However, the particular mechanism by which this EtOH/cAMP-PKA interaction occurs has not yet been clarified in detail.

Considering that acetaldehyde has proven to be responsible for many different EtOH-induced behaviors, and that this alcohol activates the cAMP-PKA signaling pathway, we hypothesized that acetaldehyde might be ultimately responsible for the activation of this intracellular pathway. Hence, we aimed to study the role of central acetaldehyde on EtOH-induced PKA activation. To do this, we used different pharmacological agents that have previously proven effective in preventing central acetaldehyde formation following EtOH administration, such as LA [7,9,27], AT [12-14], and D-Pen [16,18]. We have assessed whether these pharmacological manipulations alter the PKA activity induced by EtOH administration.
PKA activity was evaluated taking into consideration the results of such activation using a subset of phosphorylatable substrate consensus motifs as a kinase footprint [23,24].

**Material and methods**

**Animals**

For this work, we used a total of 4–6 male CD-1 mice (Harlan, Interfauna) per group. All animals, aged 4–6 weeks upon arrival, were housed 3 per cage in an acclimated quarantine room, in which they remained for a week. After this quarantine period, mice were moved into a colony room at least one week before the experiments started. The colony room was maintained at a temperature of 21 ± 1°C and controlled under a 12-h light/dark cycle (lights on at 8 a.m.). Food and water were provided ad libitum throughout the study. All experimental procedures complied with the European Community Council Directive (2010/63/EU).

**Drugs**

EtOH, purchased from Panreac (Barcelona, Spain), was diluted to 20% (v/v) in 0.9% (w/v) physiological saline, which was also used as the vehicle. LA (Sigma-Aldrich Química, Madrid, Spain) was dissolved in Dulbecco’s phosphate-buffered saline, using a minimum possible amount of 1 M NaOH solution. The final pH of the resulting solution was 7 ± 1. AT and D-Pen (Sigma-Aldrich Química, Madrid, Spain) were both diluted in 0.9% (w/v) physiological saline.

**Experimental procedure**

All animals (n = 4–6 per group) were moved from their home cages to the procedure room 30 minutes before the start of the experiment to allow them to acclimatize to the environmental conditions. Three different experimental phases were conducted. In the first experiment, animals were pretreated with LA (0 or 100 mg/Kg, i.p.), and 30 minutes later EtOH (0 or 2.5 g/Kg, i.p.) was injected [7]. In the second experiment, AT (0 or 1 g/Kg, i.p.) was administered 4h prior to the EtOH challenge (0 or 2.5 g/Kg, i.p.) [12]. Lastly, in the third
experiment D-Pen (0 or 75 mg/Kg, i.p.) was administered 30 minutes before EtOH (0 or 2.5 g/Kg, i.p.) injection [14]. For all three experimental phases, animals were sacrificed 15 minutes after EtOH administration. Brains were immediately removed and dissected. PKA activity was measured using a subset of phosphorylatable substrate consensus motifs as a kinase footprint [23,24].

**Western blot**

For determination of PKA, 20 μg of protein extract from three brain structures (frontal cortex, striatum and hypothalamus; n = 4–6 per group) were run in duplicate into pure nitrocellulose membranes (0.45 mm) using standard techniques. Membranes were incubated overnight with a primary antiphosphorylated PKA substrate motif (1:6,000; Cell Signaling Technology, Beverly, MA) and then with HRP-conjugated secondary antibody anti-rabbit (1:20,000). Anti-GAPDH antibody (1:40,000; Sigma-Aldrich Química) was used as a loading control. Proteins were visualized using an enhanced chemi-luminescence system (Amersham Pharmacia Biotech, Madrid, Spain). The relative intensities were quantified and analyzed individually with Sigma-Gel image analysis software version 1.0 (Jandel Scientific, Madrid, Spain). Density values were averaged to obtain a normalized value. The average of these normalized values in the saline-treated group was arbitrarily considered to be 100% and then used for calculations involving all the different experimental manipulations.

**Statistical analysis**

For the analysis, the relative increase was considered to be the dependent variable. A one- or two-way ANOVA was performed when required. Newman-Keuls post hoc comparisons were used in experiments 1 and 3. The Tukey HSD post hoc test was applied in the analyses of the results obtained in experiment 2 because it is highly conservative against type I error and it does not require a significant interaction between factors [28]. All statistical analyses were performed using the Statistica 9.0 (StarSoft, Tulsa, OK, USA) software package.
Results

**PKA activation after the administration of α-lipoic acid**

In this experiment, we assessed the role of the catalase-H2O2 system in the EtOH-induced activation of the PKA. Pretreatment with the H2O2 scavenger LA resulted in a decreased intensity of the immunoreactive bands in all the structures in the study. Figure 1 reflects the effects of LA pretreatment on the EtOH-induced activation of PKA on the cortex (A), striatum (B), and hypothalamus (C). Two-way ANOVA (pretreatment x treatment) showed a lack of effect both for pretreatment and treatment factor in cortex and striatum. A significant main effect was found for the treatment [F(1,18) = 11.25, p < 0.01] and pretreatment [F(1,18) = 19.03, p < 0.01] factor in the hypothalamus. Both factors (pretreatment x treatment) interact in all the structures of the study: the cortex [F(1,17) = 7.76, p < 0.05], striatum [F(1,18) = 10.27, p < 0.01] and hypothalamus [F(1,18) = 13.69, p < 0.01]. Post hoc comparisons indicate an activating effect of the PKA after EtOH injection when compared to its saline control for cortex (p < 0.05), striatum (p < 0.05), and hypothalamus (p < 0.01). Furthermore, no statistical differences were found in the PKA fingerprint among groups pretreated with LA for all the structures in the study.

**PKA activation after the administration of aminotriazole**

Here, we have studied the role of the catalase-H2O2 system in EtOH-induced activation of PKA. Pretreatment with the catalase inhibition agent AT resulted in a reduction in the PKA activity elicited by EtOH. Figure 2 shows the effect of AT administration on the PKA fingerprint in (A) cortex, (B) striatum, and (C) hypothalamus. Two-way ANOVA (pretreatment x treatment) showed a significant main effect for EtOH treatment in the cortex [F(1,18) = 5.71, p < 0.05] and hypothalamus [F(1,18) = 10.40, p < 0.05]. The pretreatment factor was found to be significant in the hypothalamus [F(1,18) = 6.66, p < 0.05]. An interaction effect (pretreatment x treatment) was also found in the striatum [F(1,17) = 8.62, p < 0.05].
However, no significant interaction was found for the cortex \( F(1,18) = 2.51 \) or the hypothalamus \( F(1,18) = 2.55 \). Thus, we selected Tukey’s HSD post hoc comparisons to analyze the three structures in this experiment. Tukey’s HSD post hoc analyses demonstrated that pretreatment with EtOH increased PKA activity for all the structures in the study. Moreover, no statistical differences were found among groups pretreated with AT.

**PKA activation after the administration of D-penicillamine**

Here, we aimed to study the role of centrally formed acetaldehyde on ethanol-elicited PKA activation. Pretreatment with the acetaldehyde inactivating agent D-pen produced a reduction in the EtOH-induced activation of PKA. Figure 3 reflects the effect of D-pen administration on EtOH-activated PKA in (A) cortex, (B) striatum, and (C) hypothalamus. Two-way ANOVA (pretreatment x treatment) showed a significant main effect for EtOH treatment in all the structures in the study, i.e., the cortex \( F(1,15) = 25.77, p < 0.01 \), striatum \( F(1,18) = 12.58, p < 0.01 \), and hypothalamus \( F(1,22) = 5.19, p < 0.05 \). Moreover, D-pen pretreatment was found to be significant in the cortex \( F(1,15) = 26.35, p < 0.01 \), striatum \( F(1,18) = 15.43, p < 0.01 \), and hypothalamus \( F(1,22) = 15.78, p < 0.01 \). Both factors (pretreatment x treatment) interact in the cortex \( F(1,15) = 10.22, p < 0.01 \), striatum \( F(1,18) = 13.52, p < 0.01 \), and hypothalamus \( F(1,22) = 12.83, p < 0.01 \). Post hoc comparisons indicate an activating effect of PKA after EtOH injection when compared to its saline control for all the structures in the study, \( p < 0.01 \). Furthermore, no significant differences were found among groups pretreated with D-pen.

**Discussion**

In this work, we aimed to explore the role of centrally formed acetaldehyde on EtOH-induced activation of PKA. In agreement with previously published data [23,24], our results show that EtOH administration to mice elicited PKA activation in different brain areas (prefrontal...
cortex, striatum, and hypothalamus). Catalase-H2O2 system blockade by pretreatment with LA and AT resulted in a reduction in EtOH-induced activation of PKA. Furthermore, pretreatment with the acetaldehyde inactivator D-Pen also produced a decrease in PKA activity observed after EtOH administration. These data suggest a role of centrally formed acetaldehyde in EtOH-elicited PKA activation.

The effects of EtOH on PKA activity have been shown in neuronal cell cultures [29,30]. Again, in vivo experiments have demonstrated an up-regulation of the cAMP-PKA cascade after EtOH administration [22,23,31]. In the present work, we aimed to explore the functional consequences of brain acetaldehyde modulation on EtOH-stimulated PKA activity. Thus, we have used a subset of phosphorylatable consensus motifs as a PKA-activated fingerprint [22,23]. Previous literature has demonstrated that EtOH administration promotes an increased steady response at different band intensities (90, 100 and 140 kDa) in mice brains [22,23]. Consistent with these results, we have found a similar band-enhanced response after EtOH administration in the areas in the study. Conversely, when acetaldehyde manipulations were administered prior to EtOH, the densitometric analysis indicated a reduction in the band intensity when compared to control animals. These data suggest that centrally formed acetaldehyde is critical to further activate the cAMP-PKA cascade promoted by EtOH exposure.

Acetaldehyde has been suggested as a neuroactive agent responsible for different EtOH neurobehavioral effects [32]. Thus, in order to ascertain the role of acetaldehyde in EtOH-induced activation of PKA, we have used three pharmacological approaches. Firstly, we have used LA as an H2O2 scavenging agent. This compound acts as an H2O2 scavenger and it has been demonstrated that, if administered systemically, it modulates brain H2O2 levels, and consequently catalase activity [7,27]. Secondly, we used the noncompetitive catalase inhibitor AT. This compound can also be administered systemically, and prevents acetaldehyde formation after EtOH administration [3,33]. Finally, we have used the acetaldehyde-sequestering agent D-Pen, which prevents interaction between the centrally formed
acetaldehyde and the neural substrate [14,15,17]. Despite the fact that these agents differed in their molecular mechanism of action to block acetaldehyde production, our results showed that EtOH metabolism at a central level appears to be critical to elicit further PKA activation.

A great body of evidence has demonstrated that the activation of the cAMP signaling cascade appears to be a major cellular response to EtOH in vivo and in different cell preparations [21,23,30]. However, the particular mechanism by which this activation occurs has still not been clarified in detail. In this respect, recently published data from our laboratory have demonstrated that intracellular calcium (Ca2+) appears to be a key factor in this EtOH-induced PKA activation [34-36]. Thus, different manipulations addressed to modulate intracellular Ca2+ levels resulted in a selective blockade of the PKA response elicited by EtOH [34]. Interestingly, it has been found that acetaldehyde administration at biologically relevant concentrations ranging from 1–10 μM promotes Ca2+ release in different cell preparations [37-40]. Moreover, these authors also found that manipulations affecting EtOH oxidation to acetaldehyde were able to modulate such acetaldehyde-mediated Ca2+ release.

At the behavioral level, the PKA signaling transduction pathway has proven to be involved in the modulation of several EtOH-induced behaviors. Manipulations of the cAMP-PKA-dependent cascade modulate EtOH intake [24], EtOH-induced sensitization [26,41], and EtOH sensitivity [42]. In this regard, previous work by our group has demonstrated that the alteration of cytoplasmic Ca2+ levels reduced EtOH intake, EtOH-induced locomotor activity, and affected EtOH sensitivity [34,35]. Given this, it has been suggested that intracellular Ca2+ levels may be a key factor that determines the cAMP-signaling response, and consequently the behavioral outcome observed after EtOH administration.

Parallel to these interesting findings, a great body of evidence has proven that central acetaldehyde plays a key role in different EtOH-promoted behaviors. Thus, manipulations focused on decreasing or blocking acetaldehyde production, such as catalase inhibition by the use of AT or acetaldehyde sequestration with the agent D-Pen, resulted in a reduction in EtOH-
induced locomotor activity [14,17], EtOH intake [15], EtOH-induced place preference [15,27], social recognition [43], loss of righting reflex [44], and anxiety [45]. Furthermore, a reduction of the brain levels of compound I by the pharmacological manipulation of the cellular oxidative state also played a critical role in the behavioral response promoted by EtOH. H2O2 scavenging with LA or Ebselen have proven to modulate EtOH-induced locomotor activity [7,36], EtOH intake [8], and EtOH-induced conditioned place preference [27].

In sum, we demonstrate that, when administered previously, acetaldehyde inactivation agents effectively inhibit PKA activation following EtOH exposure. Therefore, this work provides valuable insight into the putative intracellular mechanism through which EtOH might be exerting its effects. Moreover, these data support the idea that, through the PKA-involved intracellular Ca2+ pathway, centrally formed acetaldehyde is mainly responsible for the appearance of the psychopharmacological effects of EtOH.

**Conclusion**

We have demonstrated that the activation of the cAMP-PKA signaling cascade promoted by EtOH administration in vivo is dependent on the central catalasemic metabolism of EtOH. Thus, manipulations, which reduced the rate of centrally formed acetaldehyde, resulted in a decreased EtOH-induced activation of PKA. Moreover, all these results together with the previous literature strongly support the hypothesis of a selective release of acetaldehyde-dependent Ca2+ from the ER as the mechanism involved in the neurobehavioral effects elicited by EtOH.

**Acknowledgements**

This research was supported by a grant from the Spanish Ministerio de Ciencia e Innovacion (PSI2011-28934/ PSIC). Pablo Baliño was supported by a fellowship from the CICYT (BES-2009-024438). Ernesto Tarragon was supported at the time by Red de Trastornos Adictivos, Ministerio de Sanidad y Politica Social (RD06/0001/0028), Spain.
References


27. J.C. Ledesma, C.M.G. Aragon, Acquisition and reconditioning of ethanol-induced conditioned place preference in mice is blocked by the H(2)O(2) scavenger alpha lipoic acid, Psychopharmacology 226 (2013) 673-685.


Figure 1. PKA activation after LA administration. Immunoblot analysis and quantification of the PKA substrate. Left panels show the densitometric analysis performed to quantify the relative intensity of the bands (arbitrary units) after pretreatment with LA (0 or 100 mg/kg, i.p.) 30 minutes before EtOH (0 or 2.5 g/kg, i.p.) challenge. Right panels show a representative Western blot of the PKA fingerprint after Vehicle or EtOH administration. Anti-GAPDH blots shown equal protein loading. (A) Cortex, (B) striatum, (C) hypothalamus. Depicted is the mean ±SEM. * p < 0.05, ** p < 0.01 significantly different from its respective Vehicle control. S, saline; E, EtOH; LA, α-lipioc acid.

Figure 2. PKA activation after AT administration. Immunoblot analysis and quantification of the PKA substrate. Left panels show the densitometric analysis performed to quantify the relative intensity of the bands (arbitrary units) after pretreatment with AT (0 or 1 g/kg, i.p.) 4 hours before EtOH (0 or 2.5 g/kg, i.p.) challenge. Right panels show a representative Western blot of the PKA fingerprint after Vehicle or EtOH administration. Anti-GAPDH blots shown equal protein loading. (A) Cortex, (B) striatum, (C) hypothalamus. Depicted is the mean ±SEM. * p < 0.05, ** p < 0.01 significantly different from its respective Vehicle control. S, saline; E, EtOH; AT, aminotriazole.

Figure 3. PKA activation after D-Pen administration. Immunoblot analysis and quantification of the PKA substrate. Left panels show the densitometric analysis performed to quantify the relative intensity of the bands (arbitrary units) after pretreatment with D-Pen (0 or 75 mg/kg, i.p.) 30 minutes before EtOH (0 or 2.5 g/kg, i.p.) challenge. Right panels show a representative Western blot of the PKA fingerprint after Vehicle or EtOH administration. Anti-GAPDH blots shown equal protein loading. (A) Cortex, (B) striatum, (C) hypothalamus. Depicted is the mean ±SEM. ** p < 0.01 significantly different from its respective Vehicle control. S, saline; E, EtOH; D-Pen, D-penicillamine.
Figure 1

A

![Bar chart showing the effect of AL dose (mg/Kg) on arbitrary units.](image1)

B

![Bar chart showing the effect of LA dose (mg/Kg) on arbitrary units.](image2)

C

![Bar chart showing the effect of LA dose (mg/Kg) on arbitrary units.](image3)
Figure 2

A

<table>
<thead>
<tr>
<th>AT dose (g/Kg)</th>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arbitrary units</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>AT dose (g/Kg)</th>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arbitrary units</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th>AT dose (g/Kg)</th>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arbitrary units</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 3

A

D-Pen dose (mg/Kg)

Arbitrary units

[Bar graphs showing D-Pen dose (mg/Kg) on the x-axis and Arbitrary units on the y-axis.](#)

B

D-Pen dose (mg/Kg)

Arbitrary units

[Bar graphs showing D-Pen dose (mg/Kg) on the x-axis and Arbitrary units on the y-axis.](#)

C

D-Pen dose (mg/Kg)

Arbitrary units

[Bar graphs showing D-Pen dose (mg/Kg) on the x-axis and Arbitrary units on the y-axis.](#)